Eli Lilly LLY Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 82.8%-0.2pp | 83%0.0pp | 83%+0.4pp | 82.6%+0.9pp | 81.7%+0.4pp | |
| Net margin | 35%+3.3pp | 31.7%+0.7pp | 31%+5.1pp | 25.9%+3.2pp | 22.7%-0.8pp | |
| Returns | ||||||
| Return on equity | 107.6%+6.5pp | 101.2%+4.3pp | 96.8%+10.1pp | 86.7%+9.0pp | 77.7%-6.8pp | |
| Return on invested capital | 42%+3.7pp | 38.3%+0.9pp | 37.4%+8.0pp | 29.4%+4.0pp | 25.3%-1.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.7×+0.1× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | |
| Liquidity | ||||||
| Current ratio | 1.5×-0.1× | 1.6×0.0× | 1.5×+0.3× | 1.3×-0.1× | 1.4×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 1.4×-0.2× | 1.6×-0.2× | 1.8×-0.4× | 2.2×-0.3× | 2.4×0.0× | |
| Net debt / EBITDA | 1.1×-0.1× | 1.3×-0.1× | 1.3×-0.6× | 1.9×-0.3× | 2.3×+0.1× | |
| Per Share | ||||||
| Book value per share | $34.82+18.0% | $29.51+11.5% | $26.47+30.4% | $20.31+16.0% | $17.50+10.9% | |
| Valuation | ||||||
| Market capitalization | $821.68B-14.6% | $961.86B+40.6% | $684B-2.1% | $698.51B-5.8% | $741.66B+6.8% | |
| Price / earnings | 32.5×-14.1× | 46.6×+9.5× | 37.1×-13.5× | 50.6×-16.2× | 66.8×+1.2× | |
| Price / sales | 11.4×-3.4× | 14.8×+3.2× | 11.5×-1.6× | 13.1×-2.0× | 15.1×-0.3× | |
| Price / book | 26.3×-9.9× | 36.2×+7.5× | 28.7×-9.5× | 38.2×-8.8× | 47×-1.6× | |
| EV / EBITDA | 25.9×-10.0× | 36×+6.6× | 29.4×-9.8× | 39.2×-11.2× | 50.4×+0.1× | |
| Dividend yield | 0.7%+0.1pp | 0.6%-0.2pp | 0.8%0.0pp | 0.7%+0.1pp | 0.7%0.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Eli Lilly's ratios come from?
- Every ratio is computed from Eli Lilly's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
